Swiss Precision Meets Rising Demand in Hungary

Medistri’s $2.5 million expansion in Hungary addresses a critical shortage of sterilization capacity for the European medical device market

24 Apr 2026

The race for sterile medical infrastructure just accelerated in Eastern Europe. Medistri has officially launched its second ethylene oxide sterilization line at its Budapest facility, a $2.5 million move designed to capture a market feeling the squeeze of tightening regulations. While the site only opened its doors in early 2025, the rapid expansion signals a shift in where the industry’s heavy lifting now happens.

Ethylene oxide remains the undisputed titan of the industry, handling nearly 50% of global sterilization needs for moisture-sensitive devices. Despite environmental debates, no alternative currently matches its scale or efficacy. For manufacturers operating within the European Union, the need for Swiss-standard compliance near their production lines has turned this Hungarian hub into a regional anchor.

The timing is far from accidental. As infection control standards evolve, the margin for error for device makers has vanished. Many are now abandoning in-house efforts, choosing instead to outsource the entire lifecycle from validation and lab testing to final packaging to specialists who can shoulder the regulatory burden. Medistri has positioned itself as the primary beneficiary of this migration toward third-party experts.

The broader economic landscape supports this aggressive local growth. The global sterilization services market is on a trajectory to reach $10.64 billion by 2034, fueled by the sheer volume of single-use medical tools. By planting a deeper flag in Hungary, Medistri isn’t just adding machinery; it is securing its place in a critical growth corridor. Central Europe is no longer a peripheral market. It is the new center of gravity for medical manufacturing.